CN110882393A - Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof - Google Patents
Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof Download PDFInfo
- Publication number
- CN110882393A CN110882393A CN201811098278.1A CN201811098278A CN110882393A CN 110882393 A CN110882393 A CN 110882393A CN 201811098278 A CN201811098278 A CN 201811098278A CN 110882393 A CN110882393 A CN 110882393A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- alkaline
- hyperuricemia
- mixing
- alkaline protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 26
- 201000005569 Gout Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 108091005658 Basic proteases Proteins 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 239000000872 buffer Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- 229910052732 germanium Inorganic materials 0.000 claims description 13
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 8
- 229910052711 selenium Inorganic materials 0.000 claims description 8
- 239000011669 selenium Substances 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000005515 coenzyme Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 7
- 239000011726 vitamin B6 Substances 0.000 claims description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- 102000038379 digestive enzymes Human genes 0.000 claims description 6
- 108091007734 digestive enzymes Proteins 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- -1 alkaline elements Substances 0.000 claims 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012459 cleaning agent Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 88
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 86
- 229940116269 uric acid Drugs 0.000 abstract description 86
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 37
- 239000006047 digesta Substances 0.000 abstract description 11
- 239000013078 crystal Substances 0.000 abstract description 10
- 108090000631 Trypsin Proteins 0.000 abstract description 7
- 102000004142 Trypsin Human genes 0.000 abstract description 7
- 239000012588 trypsin Substances 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 229910001415 sodium ion Inorganic materials 0.000 abstract description 4
- 238000002425 crystallisation Methods 0.000 abstract description 3
- 230000008025 crystallization Effects 0.000 abstract description 3
- 230000000630 rising effect Effects 0.000 abstract description 3
- 230000008713 feedback mechanism Effects 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 210000003734 kidney Anatomy 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 13
- 108090000854 Oxidoreductases Proteins 0.000 description 10
- 102000004316 Oxidoreductases Human genes 0.000 description 10
- 108010092464 Urate Oxidase Proteins 0.000 description 10
- 230000029142 excretion Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229940005267 urate oxidase Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 102000010911 Enzyme Precursors Human genes 0.000 description 7
- 108010062466 Enzyme Precursors Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 229960003975 potassium Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000008288 physiological mechanism Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000219122 Cucurbita Species 0.000 description 3
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- YPSNMKHPDJVGEX-UHFFFAOYSA-L potassium;sodium;3-carboxy-3-hydroxypentanedioate Chemical compound [Na+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O YPSNMKHPDJVGEX-UHFFFAOYSA-L 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 description 1
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000000223 Solitary Kidney Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007322 compensatory function Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000082 organogermanium group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229950004176 topiroxostat Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
A preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and a preparation method thereof belong to the field of biochemical pharmacy. The principle is as follows: the enteric slow release and alkaline controllable alkaline buffer pair is applied, and the alkaline protease is a macromolecular substance, is not absorbed into blood by intestinal tracts and has no toxic or side effect; alkaline protease is used for assisting autologous trypsin to decompose intestinal tract digesta, so that uric acid wrapped by the intestinal tract digesta is fully exposed, and the uric acid is effectively neutralized face to face by an alkaline controllable buffer pair. The feedback mechanism that uric acid discharged by the intestinal tract is prevented from being absorbed into blood again along with sodium ions in food is achieved, and the continuous rising of the uric acid value is effectively prevented to generate supersaturated crystallization; and, the vicious circle in which uric acid crystals accumulate continuously. The intestinal tract alkalescent physiological environment is maintained, the blood uric acid value is kept in a beneficial range of 300-350 umol/L for a long time, and the aim of artificially throttling and controlling the application amount of uric acid is fulfilled.
Description
Technical Field
The invention relates to a preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and a preparation method thereof; in particular to a biological product, belonging to the field of biochemical pharmacy.
Technical Field
In our country, hyperuricemia and gout are the fourth chronic common disease that appears after hypertension, hyperlipidemia and hyperglycemia. The specific method for preventing and treating critical hyperuricemia, hyperuricemia and gout is implemented by applying urate oxidase, which is an antagonistic substance, in an injection form; however, urate oxidase is an foreign protein, and although the chemical modification reduces the antigen, the injection in vivo still causes the reaction of pyrogen and allergen to the people with acute constitution, and the cachexia is formed. The domestic patent technology 200710018951.1 applies urate oxidase by oral enteric method, which solves the problem of pyrogen and allergen reaction, but urate oxidase is obtained from fermentation liquor of microorganism such as ox kidney, pig liver, torula priogenes and candida, and has high cost. At present, no enterprise has mass production in China, and the national food and drug standards are also included; therefore, the large-scale clinical application of urate oxidase in China is restricted.
Uric acid is an endogenous strong antioxidant and maintains that cells in a body are not excessively oxidized by free oxygen and are prematurely weakened, aged and mutated (cancerated); in addition, the uric acid amount in blood is gradually increased along with the increase of the age of a human body, and the uric acid is a decisive substance for the long life of the human body; moreover, uric acid levels not exceeding a critical level are specific substances for maintaining daily facial image and body state rejuvenation. However, before the age of 60, if the blood uric acid value continuously exceeds the saturation level, urate crystals and stones are generated, and the kidney and bone joints are damaged; therefore, uric acid is for humans, an extremely sharp-handled and typical double-edged sword. Human, unlike other less-lived mammals, there is no specific urate oxidase to uric acid in the body, but only 2% of other non-specific urate-specific oxidases break down uric acid into soluble, non-crystallizable allantoin, which is then metabolized out of the body.
The human body uric acid is a weak organic acid, is expressed in a sodium salt form, has low solubility, is easy to crystallize, is produced by the liver and is the only generation port; two discharge ports are provided, one is a kidney discharge port accounting for 70% of total uric acid discharge and the other is an intestine discharge port accounting for 30% of total uric acid discharge, so as to maintain the supply and demand balance of the uric acid required by a human body.
The most basic reasons for high uric acid production are rich nutrition and special living habits; the secondary reason is that the uric acid metabolic enzyme group in the liver is continuously activated due to serious diseases and the like, and the uric acid amount larger than the demand is produced. If the abnormal increase amount is not controlled, the blood uric acid value is continuously increased and is continuously accumulated in the blood at high concentration, and the abnormal phenomenon is clinically called hyperuricemia; the conversion from hyperuricemia to gout is caused by the fact that the kidney can not discharge excessive uric acid load or disorder, so that uric acid supersaturated crystals are deposited and accumulated at the bone joints with high charge fields, and severe pain of non-pathogenic inflammation occurs.
When the kidney is loaded or obstructed, the compensatory function of the human body is promoted to break through 30 percent of physiological excretion of the intestinal tract, so that the excretion is forced to be increased continuously; once the intestinal tract is forced to become the main discharge channel of uric acid, the physiological environment of the intestinal tract is changed from weak alkalinity to weak acidity, and the original ecological physiological environment of the intestinal tract is thoroughly changed. In human body, 70% of lymphatic immune system is in intestinal tract and is responsible for producing vitamin B, and is the largest immune organ in vivo; once a disorder occurs, a series of extremely complex complications arise.
Aiming at critical hyperuricemia, hyperuricemia and gout, the western medicine adopts a strategy of distinguishing excessive generation type, deficient discharge type and mixed type and then coping with corresponding blockage or dredging. If liver formation is vigorous, a chemosynthesis inhibitor such as allopurin, febuxostat or topiroxostat is used to inhibit the activity of uricase group produced in liver and forcibly reduce the amount of production. This causes not only accumulation of the concentrations in the body of xanthine and hypoxanthine, precursors for producing uric acid, but also final precipitation in the kidney; while kidney function is impaired, chronic toxic reactions also occur in liver, spleen, heart, pancreas and bone marrow. The most common clinical symptoms are rash, pain in liver area, general trembling, fast heartbeat, somnolence and tinnitus; and, elevated transaminase. If the weak or old people take the chemical synthesis inhibitor for a long time, the liver and kidney cells are easily damaged, and finally two organs fail to form larger accidents; moreover, the chemical synthesis inhibitor inhibits the activity of the group of enzymes, the activities of other enzyme groups are preferentially developed, the relatively normal physiological balance is forcibly disturbed, and linked adverse reactions are generated to frost on snow; for example, hyperlipidemia, cardiac dysfunction, and the like occur. Moreover, once the administration of the chemical synthesis inhibitor is stopped or interrupted, a large amount of accumulated xanthine and hypoxanthine in the body can rapidly generate uric acid, so that the blood uric acid value is increased and the reverse feeding is caused. The method is characterized in that the situation that the gourd is pressed to gourd ladle is realized by taking a chemical synthesis inhibitor to forcibly inhibit enzymes in the liver from generating uric acid; therefore, the strong inhibition of the production of uric acid by the enzymes in the liver is a typical flood-stopping method of Gun water control, and as a result, it is useless to raise soup and stop boiling.
Uric acid is produced much like a sudden flood. The torrential flood is actually life water, and is beneficial to large and has small disadvantages; if the blockage is forced, the great disaster of breakup is caused. Obviously, the strong blockage is not intelligent, and the water discharge method must be adopted to aim at the blockage. But let out the intelligence to let out; otherwise, the situation that the gourd is pressed down to be lifted up also occurs. Two outlets are provided, and the western medicine adopts a single kidney outlet aiming at the type of hyporrhea. In particular, a chemosynthesis inhibitor of benzbromarone, probenecid and the like is used for inhibiting reabsorption of kidney tubules on uric acid so as to forcibly increase excretion of the uric acid; however, the physiological excretion function of the kidney is broken through by artificially forcibly increasing the excretion amount, so that the diseases such as soreness and weakness of waist and knees, impotence, tinnitus, waist pain, fatigue, elevation of blood creatinine value and the like are caused; moreover, when a large amount of uric acid is forcibly overloaded and is discharged by the kidney, the uric acid is easy to be attached and deposited in renal tubules, renal pelvis and ureter to form renal calculus and calculus in the ureter, thereby causing renal colic and renal function damage; this phenomenon is commonly known as gout kidneys.
Western medicine, if it is detected that the type is both the type with much production and the type with little excretion, it is judged as mixed type; the two chemical synthesis inhibitors are put on duty alternately to perform inhibition alternately, so that the harm caused by the inhibition is enlarged and complicated. In reality, due to panic and urgent psychology, it is very common and dangerous to privately use these two classes of chemical synthesis inhibitors to alternately inhibit enzyme activity in liver and kidney to treat hyperuricemia and gout.
The human body has great reaction to chemical synthesis preparations, which is particularly reflected in the toxic and side effects. The most intuitive understanding is that the transaminase and creatinine equivalent is increased due to liver and kidney damage. For example, proteins are of large molecular weight and are not permeable to the glomerular basement membrane under normal physiological conditions in humans; once kidney injury is caused by toxic and side effects of a chemical synthesis preparation, glomerular basement membranes are damaged to leak protein, and urine presents a large amount of foam and dark color which are not easy to dissipate; the early signals and the warning signs of the pathological changes of the liver and the kidney are displayed by the urine trace protein method.
The intestinal outlet of two outlets of the human body uric acid accounts for 30 percent of the total excretion of the uric acid; it excretes a large portion of uric acid, and is accompanied by reabsorption of sodium in the ingested food in the intestinal tract into the blood, forming physiological feedback. If hyperuricemia and gout occur, the excretion of the kidney and the intestines is just a great reversal value, which is an instinctive reaction made by a human body compensation mechanism; according to this physiological characteristic, the eyes should be put on the intestinal discharge opening.
Clinically, except for the application of the two chemically synthesized inhibitors, actually, a lot of natural substances specially and effectively corresponding to weakly acidic uric acid are provided. For example, various organic alkaloids extracted from plants, and various inorganic bases existing in the natural world; such as sodium carbonate, potassium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, and the like. In domestic clinic, the most basic method is to take potassium citrate sustained release tablets and potassium sodium hydrogen citrate orally and drip sodium hydroxide solution; and alkaline substances such as sodium bicarbonate tablets, but the actual effect is low. The reason for this is that the digestion products of protein, starch and fat in the intestinal tract are deeply acidified by a large amount of excess uric acid, so that the intestinal flora is disordered, sufficient vitamin B cannot be produced, and enterokinase secreted by the intestinal tract is insufficient or inactivated, so that trypsin is not fully activated to exert the due enzymolysis effect; moreover, a large amount of excessive uric acid degrades trypsin, so that the activity of the trypsin is greatly reduced, and intestinal digesta can not be fully physiologically decomposed; thus, organic and inorganic potassium, sodium carbonate, sodium bicarbonate tablets; and alkaline elements such as potassium citrate sustained-release tablets, potassium sodium hydrogen citrate and the like can only perform neutralization reaction with uric acid on the surface of intestinal digests but cannot perform the neutralization reaction with uric acid comprehensively and deeply; residual uric acid wrapped by the intestinal tract digesta is caused, and sodium ions in the intestinal tract digesta are absorbed into blood again along with the residual uric acid, so that continuous physiological feedback is formed; finally, the adverse situation that the uric acid in the intestinal tract is not controlled manually appears. Moreover, if a large amount of alkaline elements is used, the alkaline elements are easily poisoned due to uncontrollable alkalinity.
On the premise that the body does not have serious diseases, the excessive production of uric acid is the expression that the activity of the enzyme is strong, the constitution is far stronger than that of most people, and the giant panda is a human panda. Therefore, sacrificing the enzymatic activities in the liver and kidney is equivalent to artificially and forcibly killing the good physiological mechanisms of the body, which is extremely unintelligible. Based on the principle of uric acid generation and excretion of human body, the aims of reducing uric acid, eliminating uric acid crystal and treating hyperuricemia and gout are achieved without sacrificing enzyme activity in liver and kidney. Therefore, the human body evolution is not only deprived but also damaged; moreover, the method causes linked physiological adverse reactions, and the correct method is to reverse the thinking.
Although the human body does not have the specific and unique variety of urate oxidase, other 100-120 non-professional oxidase varieties aiming at uric acid exist; oxidase groups such as peroxidase, catalase, cytochrome oxidase, etc. These oxidase groups are sensitive to organic elements of magnesium, manganese, copper, selenium, germanium and zinc. On the one hand, the organic elements are used for critically activating the oxidase groups in the body, so that the oxidase groups have strong activity and can balance the amount of uric acid naturally to the best. On the other hand, the intestinal tract discharge port of uric acid is fully applied to supplement natural protein digestive enzyme suitable for intestinal tract alkalescent environment by oral administration, and strong auxiliary autologous trypsin is removed to ensure normal enzymolysis function; and, use organic element potassium and phosphate of high electric charge, happen to be due to the trend of high uric acid, digest and neutralize the surplus uric acid amount of the overflow, maintain the high value of the blood uric acid value of ordinary person; and before the age of 60 years, the application amount of uric acid is artificially controlled in a throttling manner, so that the blood uric acid value is kept at an ideal level of 300-350 umol/L. Because the molecular weight of the externally-supplemented protein digestive enzyme in the intestinal tract is extremely large, the externally-supplemented protein digestive enzyme is difficult to absorb into blood by the intestinal tract; therefore, the medicine can not participate in the physiological process of human body to cause physiological reaction, and organs such as liver, kidney, heart, pancreas and the like can be affected; moreover, the traditional Chinese medicine composition is applied to the natural digestive tract, so that no toxic or side effect exists.
Disclosure of Invention
The invention provides a preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and a preparation method thereof. The principle is as follows: applying enteric slow-release and alkalinity-controllable elements; and the protease is a macromolecular substance, is not absorbed into blood by intestinal tracts, has the characteristic of no toxic or side effect, assists the trypsin secreted by pancreas and completes the physiological decomposition of intestinal tract digesta. The elements with controllable alkalinity provide an optimum reaction environment for protease, so that intestinal digesta is fully decomposed, and uric acid wrapped by the intestinal digesta is completely exposed; the alkaline controllable elements are fully and effectively contacted with uric acid face to cause neutralization, and the intestinal non-uric acid can be absorbed in a kettle bottom sucking mode. By the method, a physiological feedback mechanism that 30-70% of uric acid discharged from intestinal tracts is completely inhibited and sodium ions in food are absorbed into blood again is effectively prevented, and the continuous rising of the uric acid value is effectively prevented to generate supersaturated crystallization; and, the vicious circle in which uric acid crystals accumulate continuously. The intestinal tract alkalescent physiological environment is maintained, the blood uric acid value is kept in a beneficial range of 300-350 umol/L for a long time, and the aim of artificially throttling and controlling the application amount of uric acid is fulfilled.
The technical problem to be solved by the invention is as follows:
1. selection of enzymes
The pH of human blood is 7.35-7.40, the pH of small intestine fluid is 7.6-7.8, and the pH of large intestine fluid is 8.4-8.55, which are both alkalescent; maintain the physiological mechanism of blood and intestinal alkalescence and exert the efficacy of the used enzyme, and the enzyme conforming to the physiological mechanism of alkalescence of a human body needs to be selected.
2. Selection of basic elements
The basic element is selected to provide an optimum reaction environment for the enzyme selected and to be sufficiently effective to contact uric acid for neutralization; also, the alkalinity can be controlled.
3. Application route and method of enzyme and alkaline element
Degrading neutral and alkaline enzymes by gastric acid to inactivate zymogen; and the alkaline element is subjected to neutralization reaction, so that the alkaline element loses efficacy, gastric enzyme and gastric secretions such as gastrodin are damaged, and the gastric function is damaged; the killing ability of miscellaneous viruses and bacteria in the diet is further weakened. Therefore, the stomach is avoided, and the selected enzyme and alkaline elements are delivered to the intestinal tract in a weakly alkaline environment for slow release application.
4. Enteric material
The enteric material which can avoid the hyperacidity and can be disintegrated and released in the intestinal tract is selected.
5. Blood cleaning
Critical hyperuricemia, hyperuricemia and gout, and accumulating metabolites in blood to form garbage of blood metabolites; therefore, the metabolites in the blood must be efficiently cleared.
6. Activating proenzyme
The activity of the oxidase group and the selected enzyme in vivo is improved.
7. Selection of coenzymes
Vitamin B is used as coenzyme, so that the vitamin B which is lost due to intestinal flora imbalance caused by the acidity of the intestinal environment is met, and the metabolism of the organism is promoted; it also needs to activate the selected enzyme and the zymogen of the in vivo oxidase group, and improve the enzyme activity.
The technical scheme adopted by the invention for solving the technical problems is as follows:
1. selection of enzymes
Alkaline protease is selected. Alkaline proteases are the only enzyme species that have enzymatic reactions in alkaline environments; has the commonness similar to urate oxidase, is suitable for alkaline environment, and accords with the physiological mechanism of intestinal weakly alkaline original ecology. The molecular weight is 2-3 thousands, the powder is light brown, yellow brown to white, is suitable for the environment with the pH of 7.5-10.5, the applicable temperature range is 30-60 ℃, the enzyme activity is 1-200 thousands u/g, and the method is described in national food standard GB/T23527-2009.
2. Selection of basic elements
A phosphoric acid buffer pair of dipotassium hydrogen phosphate and potassium dihydrogen phosphate with controllable alkalinity and pH of 7.1-9.0 is applied, and the phosphoric acid buffer pair is in the standards of national food Standard GB25560-2010 and Chinese pharmacopoeia; and a carbonic acid buffer pair of sodium carbonate and sodium bicarbonate with controllable alkalinity and pH of 7.1-9.0, the national food standards GB1886.1 and GB1886.2, and the Chinese pharmacopoeia standards.
3. Application route and method of enzyme and alkaline element
The alkaline protease and the buffer with controllable alkalinity are equivalent, and are respectively coated by enteric materials, and the enteric materials are orally taken to be delivered to intestinal tracts for disintegration, and contents are slowly released.
4. Enteric material
Applying enteric polymer cellulose solution and finished enteric capsules.
5. Blood cleaning
Organic germanium 132 is applied. Among numerous elements, organogermanium is the only substance with high-efficiency blood purification effect. The principle is as follows: germanium, which is trapped between metals and nonmetals and has a charge affinity for metabolites in blood; because germanium is not accumulated in the body and must be discharged out of the body in 24 hours, the metabolite in the blood is attached by using the characteristic, and the blood metabolite such as the excessive uric acid is efficiently and auxiliarily eliminated; national New resource food Q3210NZ 40-2003.
6. Activating proenzyme
Organic magnesium, manganese, copper, selenium, germanium, potassium and zinc elements in the trace elements are used for critically activating oxidase groups and alkaline zymogen in the body, so that the enzyme activity is improved.
7. Selection of coenzymes
The elemental vitamin B6 is applied to assist in activating zymogens of alkaline protease and self-enzyme and increasing enzyme activity; promoting metabolism of human body.
The invention has the beneficial effects that:
1. the alkaline protease assists pancreatic secreted trypsin to decompose intestinal tract digesta into small peptides and amino acids, so that the decomposition rate and the absorption rate of ingested substances are improved; the uric acid wrapped by the intestinal tract digesta is fully exposed, and the uric acid is neutralized by effectively and face-to-face contact of the alkaline controlled buffer pair. Completely inhibiting 30-70% of uric acid discharged from intestinal tracts and absorbing into blood again along with sodium ions in food, and preventing supersaturated crystallization from occurring in continuous rising of blood uric acid value; and, the vicious circle in which uric acid crystals accumulate continuously. Effectively maintains the alkalescent physiological environment of the intestinal tract, maintains the blood uric acid value in a beneficial range of 300-350 umol/L for a long time, and achieves the aim of artificially throttling and controlling the application amount of uric acid.
2. The alkaline protease and the alkaline buffer with controllable alkalinity are equivalent, so that uric acid in the intestinal tract is neutralized into salt and urea which are dissolved in water and are discharged out of the body along with intestinal tract digesta without being metabolized by the liver and the kidney; therefore, liver and kidney damage caused by taking Chinese and western medicines does not occur, and transaminase and creatinine values in blood are not increased.
3. With the elimination of the uric acid in the intestinal tract, when the blood uric acid value is reduced to be below 500umol/L, the condition of operable operation is caused for large uric acid crystals and stones; small uric acid crystals and stones are also caused to flow back into blood because of the isoosmotic autolysis into thin and soft fluid due to the high-low fall of the huge uric acid concentration in the body; the returned uric acid is neutralized and digested when being fed back by the intestinal tract; finally, small uric acid crystals and calculi are indirectly eliminated.
4. Small uric acid crystals and stones are dissolved into fluid uric acid by isotonic autolysis, so that the conditions of negative pressure suction by a vacuum pump and rapid minimally invasive surgery are also caused; thereby greatly shortening the time, pain and cost of indirect dissolution and elimination.
5. The alkaline protease is produced in large scale in China for many years, is widely applied to industries such as food, biochemical raw material extraction, fine chemical industry, organic chemical industry, daily chemical industry and the like, and has wide application, low cost and strong market competition. The alkaline protease is applied to preventing and treating critical hyperuricemia, hyperuricemia and gout, so that the application range of the alkaline protease is expanded, and the application value is improved; and thoroughly get rid of the limitation of single application of urate oxidase, and avoid the disadvantages of high price, various defects in application and incapability of overcoming the defects.
6. Organic magnesium, manganese, copper, selenium, germanium, potassium and zinc are used for activating zymogen, so that the critical activity of an oxidase group in vivo and the applied alkaline protease is improved, and the application amount of the alkaline protease is reduced.
7. The application of the organic germanium in blood cleaning achieves the aim of safely and quickly removing metabolites in blood.
8. The vitamin B6 is used as coenzyme, which not only makes up the deficiency of the coenzyme in the intestinal tract of the patient, but also improves the enzymolysis effect.
9. The alkaline protease is applied in enteric-coated sustained release, which not only accords with the physiological mechanism of intestinal alkalescence, but also is safe and effective.
10. The alkaline protease is roughly prepared, so that the activity of the final product enzyme reaches 1-5 ten thousand u/g, and the final product enzyme is prepared into a food-grade product for application; further refining to ensure that the enzyme activity of the final product reaches 5-10 ten thousand u/g, and preparing the final product into a health-care product for application; and further removing foreign protein and decoloring to ensure that the activity of the enzyme of the final product reaches 50-60 mu/g, and preparing the final product into a pharmaceutical grade oral product for application.
The present invention will be further described with reference to the following examples.
Specific example 1 encapsulating: uniformly mixing alkaline protease and a phosphoric acid buffer pair of dipotassium hydrogen phosphate and potassium dihydrogen phosphate, wherein the pH value of the phosphoric acid buffer pair is 10-70% of the weight of the alkaline protease and is 7.1-9.0; adding enteric polymer cellulose solution, mixing, and spray drying to obtain yellowish brown granule. Uniformly mixing vitamin B6 accounting for 0.001-2.0% of the weight of alkaline protease, 0.001-0.5% of each of organic magnesium, manganese, copper, selenium, zinc and potassium and 0.001-1.0% of organic germanium element by a mixer; adding enteric polymer cellulose solution, mixing, and spray drying to obtain white fine particles. Yellow brown and white particles were mixed at a ratio of 1: mixing the mixture in a mixer according to the proportion of 1-6, and filling the enteric-coated capsules to obtain finished products. The traditional Chinese medicine is taken before meals three times a day, and 1-5 granules are taken each time; the shelf life is 18 months when stored at 5 ℃ and more than 6 months when stored at 25 ℃.
Specific example 2 food preparation: adding alkaline protease, sodium carbonate with pH of 7.1-9.0 and 10-70% of the weight of the alkaline protease and sodium bicarbonate into a mixing machine for uniformly mixing, adding an enteric polymer cellulose solution for wetting and uniformly mixing, preparing into yellow brown small particles by a granulator, and drying in a dryer at 25-30 ℃ for later use; vitamin B6 accounting for 0.001-2.0% of the weight of the alkaline protease, organic magnesium, manganese, copper, selenium, zinc and potassium which account for 0.001-0.5% of the weight of the alkaline protease and organic germanium which accounts for 0.001-1.0% of the weight of the alkaline protease are added into a mixer to be mixed uniformly, an enteric polymer cellulose solution is added to be wetted and mixed uniformly, white small particles are prepared by a granulator, and the white small particles are dried in a dryer at 35-55 ℃ for standby. Mixing the yellow brown and the white small particles in a mixing machine according to the proportion of 1: 1-6, adding the enteric polymer cellulose solution to wet and mix uniformly, making the mixture into tablets and balls by using a tablet making machine and a pill making machine, drying the tablets and the balls in a drying machine at the temperature of 30-37 ℃, and coating the tablets and the balls in a coating machine by using the enteric polymer cellulose solution to obtain a finished product. The food is eaten before meals three times a day, and 1-5 tablets/tablet are eaten each time; the shelf life is 18 months when stored at 5 ℃ and more than 6 months when stored at 25 ℃.
Claims (1)
1. A preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and a preparation method thereof are characterized by comprising enteric materials, protein digestive enzyme, alkaline elements, activators, blood-cleaning agents, coenzymes, finished product processes and a using and storing method, and the preparation method comprises the following specific operation steps:
(1) the enteric material is enteric polymer cellulose solution and finished enteric capsule shell;
(2) the protein digestive enzyme is alkaline protein digestive enzyme with the activity of 1-200 ten thousand u/g;
(3) the alkaline elements are phosphoric acid buffer pairs of dipotassium hydrogen phosphate and monopotassium phosphate with the pH value of 7.1-9.0, and carbonic acid buffer pairs of sodium carbonate and sodium bicarbonate with the pH value of 7.1-9.0;
(4) the activator is organic trace elements of magnesium, manganese, copper, selenium, germanium, potassium and zinc;
(5) a blood clearing agent which is a trace element of organic germanium 132;
(6) a coenzyme which is vitamin B6;
(7) finished product production process
① Capsule for infusion
Mixing alkaline protease, phosphoric acid buffer pairs of dipotassium hydrogen phosphate and potassium dihydrogen phosphate, wherein the pH value of the phosphoric acid buffer pairs is 7.1-9.0, the weight of the phosphoric acid buffer pairs is 10-70%, adding an enteric polymer cellulose solution, mixing uniformly, and putting the mixture into a spray dryer to form yellow brown particles for later use; mixing 0.001-2.0% of vitamin B6, 0.001-0.5% of organic magnesium, manganese, copper, selenium, zinc and potassium and 0.001-1.0% of organic germanium element by weight of alkaline protease in a mixer, adding enteric polymer cellulose solution, mixing uniformly, and adding into a spray dryer to obtain white particles for later use; uniformly mixing the yellow brown particles and the white particles in a mixing machine according to the proportion of 1: 1-6, and filling enteric-coated capsules to obtain finished products;
② food product
Adding alkaline protease, sodium carbonate with pH of 7.1-9.0 and 10-70% of the weight of the alkaline protease and sodium bicarbonate into a mixing machine for uniformly mixing, adding an enteric polymer cellulose solution for wetting and uniformly mixing, preparing into yellow brown small particles by a granulator, and drying in a dryer at 25-30 ℃ for later use; vitamin B6 accounting for 0.001-2.0% of the weight of the alkaline protease, organic magnesium, manganese, copper, selenium, zinc and potassium which account for 0.001-0.5% of the weight of the alkaline protease and organic germanium which accounts for 0.001-1.0% of the weight of the alkaline protease are added into a mixer to be mixed uniformly, an enteric polymer cellulose solution is added to be wetted and mixed uniformly, white small particles are prepared by a granulator, and the white small particles are dried in a dryer at 35-55 ℃ for standby; uniformly mixing the yellow brown and the white small particles in a mixing machine according to the proportion of 1: 1-6, adding the enteric polymer cellulose solution to wet and uniformly mix, making the yellow brown and the white small particles into tablets and balls by using a tablet making machine and a pill making machine, drying the tablets and the balls in a drying machine at the temperature of 30-37 ℃, and coating the tablets and the balls in a coating machine by using the enteric polymer cellulose solution to obtain a finished product;
(8) method of use and storage
The capsules are taken before meals three times a day, and 1-5 capsules are taken each time; the food is eaten before meals three times a day, and 1-5 tablets/granule is eaten each time; the capsule and food can be stored at 5 deg.C for 18 months, and at 25 deg.C for more than 6 months.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811098278.1A CN110882393A (en) | 2018-09-07 | 2018-09-07 | Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811098278.1A CN110882393A (en) | 2018-09-07 | 2018-09-07 | Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110882393A true CN110882393A (en) | 2020-03-17 |
Family
ID=69745695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811098278.1A Withdrawn CN110882393A (en) | 2018-09-07 | 2018-09-07 | Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110882393A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920942A (en) * | 2020-08-24 | 2020-11-13 | 深圳前海鹰岗生物科技有限公司 | Polymer microneedle for rapidly dissolving tophus and preparation method and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739558A (en) * | 2005-09-02 | 2006-03-01 | 颜怀玮 | Dietotherapeutic product for preventing and treating primary and secondary urate calculi, gout and acalcerosis and its prepn process |
| CN101168052A (en) * | 2007-10-26 | 2008-04-30 | 西安交通大学 | Enteric coated preparation for preventing and treating hyperuricemia and gout |
| US8486999B2 (en) * | 2009-08-06 | 2013-07-16 | Nissan Chemical Industries, Ltd. | Long-chain oxyaminopolyol based gelator and gel |
| CN105982921A (en) * | 2015-02-25 | 2016-10-05 | 北京世健联合医学科学研究院（普通合伙） | Composition for treating gout and application thereof |
| CN106902349A (en) * | 2017-03-07 | 2017-06-30 | 云南中医学院 | A kind of preparation and application of oral anti-trioxypurine medicine |
| CN108014329A (en) * | 2018-01-19 | 2018-05-11 | 汪群力 | It is a kind of to aid in removing composition of remaining and infiltration type ventilation calculus and preparation method thereof in operation |
-
2018
- 2018-09-07 CN CN201811098278.1A patent/CN110882393A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739558A (en) * | 2005-09-02 | 2006-03-01 | 颜怀玮 | Dietotherapeutic product for preventing and treating primary and secondary urate calculi, gout and acalcerosis and its prepn process |
| CN101168052A (en) * | 2007-10-26 | 2008-04-30 | 西安交通大学 | Enteric coated preparation for preventing and treating hyperuricemia and gout |
| US8486999B2 (en) * | 2009-08-06 | 2013-07-16 | Nissan Chemical Industries, Ltd. | Long-chain oxyaminopolyol based gelator and gel |
| CN105982921A (en) * | 2015-02-25 | 2016-10-05 | 北京世健联合医学科学研究院（普通合伙） | Composition for treating gout and application thereof |
| CN106902349A (en) * | 2017-03-07 | 2017-06-30 | 云南中医学院 | A kind of preparation and application of oral anti-trioxypurine medicine |
| CN108014329A (en) * | 2018-01-19 | 2018-05-11 | 汪群力 | It is a kind of to aid in removing composition of remaining and infiltration type ventilation calculus and preparation method thereof in operation |
Non-Patent Citations (3)
| Title |
|---|
| 王沛主编: "《制药工艺学》", 31 August 2017, 北京：中国中医药出版社 * |
| 袁成玉主编: "《无公害海参饲料生产与应用技术》", 31 August 2015, 沈阳：辽宁科学技术出版社 * |
| 陈其福主编: "《神秘的二十一世纪锗》", 31 October 2007, 上海：上海三联书店 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920942A (en) * | 2020-08-24 | 2020-11-13 | 深圳前海鹰岗生物科技有限公司 | Polymer microneedle for rapidly dissolving tophus and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stanely Mainzen Prince et al. | Antioxidant action of Tinospora cordifolia root extract in alloxan diabetic rats | |
| US5051253A (en) | Use of polyacrylates to reduce proteolytic activity in the human intestinal tract | |
| CN1961957A (en) | Anti-aging colon absorption preparation | |
| US4695457A (en) | Enzyme composition acting as a digestion promoter on various levels in the alimentary tract, and a method for facilitating digestion | |
| FR2771009A1 (en) | Biostimulant compositions contain active plant matter and a mineral with ion exchange and sorption properties | |
| CN109641019A (en) | For treating or preventing the composition and method of oxalates associated disease | |
| WO2016000508A1 (en) | Chinese herbal medicine for treating gout and preparation method thereof | |
| KR20020006114A (en) | Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body | |
| CN110882393A (en) | Preparation for preventing and treating critical hyperuricemia, hyperuricemia and gout and preparation method thereof | |
| CN110916200A (en) | Uric acid reducing composition and preparation method thereof | |
| CN109044988A (en) | A kind of metformin hydrochloride medicinal composition and its preparation method and application | |
| US7026160B2 (en) | Oral bacteriotherapy compositions and methods | |
| KR20050076104A (en) | Composition for improvement of cardiovascular disease | |
| Grossman | The physiology of secretin | |
| CN109381465A (en) | Wo Nuolazan is preparing the application in antigout preparation | |
| AU709625B2 (en) | Medical application of bromelain | |
| CN101480412A (en) | Honeybee four-treasure for treating prostatosis | |
| Selle et al. | The effect of enteric-coated pancreatin on fat and protein digestion of depancreatized dogs | |
| CN115152998A (en) | Health food for treating critical hyperuricemia, hyperuricemia and gout | |
| CN101692902A (en) | Food compositions for lowering and releasing uric acid and preventing gout | |
| KR100484428B1 (en) | Natural foods for improving constipation | |
| JPH02215723A (en) | Blood pressure regulating agent | |
| CN110250525A (en) | A kind of composition composition and preparation method thereof for gut purge before enteroscopy | |
| CN100569242C (en) | The squash polyoses enteric coated preparation | |
| CN110250548A (en) | It is a kind of to recombinate compound produce hydrogen microcapsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Front desk of Henri North Road vocal music Hotel, Anbu Town, Chaoan District, Chaozhou City, Guangdong Province Applicant after: Wang Changyong Address before: 730030 Silver Road, Gansu, Lanzhou, No. 36 Applicant before: Wang Changyong |
|
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200317 |